ASPIRA PATHLAB & DIAGNOSTICS | THYROCARE TECHNOLOGIES | ASPIRA PATHLAB & DIAGNOSTICS / THYROCARE TECHNOLOGIES |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -13.6 | 54.0 | - | View Chart |
P/BV | x | 2.6 | 6.5 | 39.7% | View Chart |
Dividend Yield | % | 0.0 | 2.8 | - |
ASPIRA PATHLAB & DIAGNOSTICS THYROCARE TECHNOLOGIES |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ASPIRA PATHLAB & DIAGNOSTICS Mar-23 |
THYROCARE TECHNOLOGIES Mar-23 |
ASPIRA PATHLAB & DIAGNOSTICS / THYROCARE TECHNOLOGIES |
5-Yr Chart Click to enlarge
|
||
High | Rs | 75 | 917 | 8.2% | |
Low | Rs | 26 | 416 | 6.2% | |
Sales per share (Unadj.) | Rs | 14.0 | 99.5 | 14.1% | |
Earnings per share (Unadj.) | Rs | -0.1 | 12.2 | -0.7% | |
Cash flow per share (Unadj.) | Rs | 1.5 | 19.5 | 7.5% | |
Dividends per share (Unadj.) | Rs | 0 | 18.00 | 0.0% | |
Avg Dividend yield | % | 0 | 2.7 | 0.0% | |
Book value per share (Unadj.) | Rs | 12.4 | 100.1 | 12.4% | |
Shares outstanding (eoy) | m | 10.29 | 52.93 | 19.4% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.6 | 6.7 | 53.5% | |
Avg P/E ratio | x | -583.7 | 54.8 | -1,064.8% | |
P/CF ratio (eoy) | x | 34.6 | 34.2 | 101.1% | |
Price / Book Value ratio | x | 4.1 | 6.7 | 61.0% | |
Dividend payout | % | 0 | 148.0 | -0.0% | |
Avg Mkt Cap | Rs m | 518 | 35,277 | 1.5% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 56 | 1,062 | 5.3% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 145 | 5,267 | 2.7% | |
Other income | Rs m | 3 | 84 | 3.8% | |
Total revenues | Rs m | 148 | 5,351 | 2.8% | |
Gross profit | Rs m | 16 | 1,237 | 1.3% | |
Depreciation | Rs m | 16 | 387 | 4.1% | |
Interest | Rs m | 4 | 48 | 8.6% | |
Profit before tax | Rs m | -1 | 886 | -0.1% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 0 | 242 | 0.0% | |
Profit after tax | Rs m | -1 | 644 | -0.1% | |
Gross profit margin | % | 11.0 | 23.5 | 46.9% | |
Effective tax rate | % | 0 | 27.4 | -0.0% | |
Net profit margin | % | -0.6 | 12.2 | -5.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 59 | 3,468 | 1.7% | |
Current liabilities | Rs m | 16 | 1,509 | 1.1% | |
Net working cap to sales | % | 29.5 | 37.2 | 79.5% | |
Current ratio | x | 3.7 | 2.3 | 160.8% | |
Inventory Days | Days | 88 | 218 | 40.2% | |
Debtors Days | Days | 590 | 6 | 10,008.0% | |
Net fixed assets | Rs m | 115 | 4,881 | 2.4% | |
Share capital | Rs m | 103 | 529 | 19.4% | |
"Free" reserves | Rs m | 25 | 4,768 | 0.5% | |
Net worth | Rs m | 128 | 5,298 | 2.4% | |
Long term debt | Rs m | 10 | 0 | - | |
Total assets | Rs m | 173 | 8,348 | 2.1% | |
Interest coverage | x | 0.8 | 19.3 | 4.1% | |
Debt to equity ratio | x | 0.1 | 0 | - | |
Sales to assets ratio | x | 0.8 | 0.6 | 132.1% | |
Return on assets | % | 1.9 | 8.3 | 22.9% | |
Return on equity | % | -0.7 | 12.1 | -5.7% | |
Return on capital | % | 2.4 | 17.6 | 13.6% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0.7 | 0.0% | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | 36 | 0.0% | |
Fx inflow | Rs m | 0 | 38 | 0.0% | |
Fx outflow | Rs m | 0 | 36 | 0.0% | |
Net fx | Rs m | 0 | 2 | 0.0% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 0 | 1,293 | -0.0% | |
From Investments | Rs m | 2 | -390 | -0.4% | |
From Financial Activity | Rs m | -9 | -862 | 1.1% | |
Net Cashflow | Rs m | -8 | 41 | -19.0% |
Indian Promoters | % | 18.7 | 71.1 | 26.3% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 17.8 | - | |
FIIs | % | 0.0 | 2.9 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 81.3 | 28.9 | 281.3% | |
Shareholders | 1,512 | 64,823 | 2.3% | ||
Pledged promoter(s) holding | % | 0.0 | 100.0 | - |
Compare ASPIRA PATHLAB & DIAGNOSTICS With: APOLLO HOSPITALS DR. LAL PATHLABS NARAYANA HRUDAYALAYA METROPOLIS HEALTHCARE KIMS
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | ASPIRA PATHLAB & DIAGNOSTICS | THYROCARE TECHNOLOGIES | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | 1.27% | -0.11% | -0.26% |
1-Month | -2.29% | 7.45% | -0.35% |
1-Year | -3.03% | 45.67% | 53.39% |
3-Year CAGR | 2.29% | -14.65% | 14.81% |
5-Year CAGR | -1.66% | 5.83% | 19.73% |
* Compound Annual Growth Rate
Here are more details on the ASPIRA PATHLAB & DIAGNOSTICS share price and the THYROCARE TECHNOLOGIES share price.
Moving on to shareholding structures...
The promoters of ASPIRA PATHLAB & DIAGNOSTICS hold a 18.7% stake in the company. In case of THYROCARE TECHNOLOGIES the stake stands at 71.1%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of ASPIRA PATHLAB & DIAGNOSTICS and the shareholding pattern of THYROCARE TECHNOLOGIES.
Finally, a word on dividends...
In the most recent financial year, ASPIRA PATHLAB & DIAGNOSTICS paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of -0.0%.
THYROCARE TECHNOLOGIES paid Rs 18.0, and its dividend payout ratio stood at 148.0%.
You may visit here to review the dividend history of ASPIRA PATHLAB & DIAGNOSTICS , and the dividend history of THYROCARE TECHNOLOGIES.
For a sector overview, read our pharmaceuticals sector report.
Asian stocks got off to a positive start on Monday ahead of the Federal Reserve's policy meeting later in the week.